Home - HealthTech Innovation Days

October 5th & 6th 2020

0

Days in Paris

0

International actors in HealthTech Innovation

0

Conferences and expert panel discussions on new trends in research & development and growth improvement

Our ambition

The HealthTech Innovation Days drive and foster collaborations within the European healthcare ecosystem.

This event features conferences and private meetings between innovative European Biotech, Medtech and Digital health companies, pharmaceutical companies, life sciences specialized investors, healthcare experts, KOLs and institutional representatives.

The HTID® demonstrates that access to innovative care for all depends on the right funding and partnership in-between actors in health and finance.

This second edition hold on October 5th & 6th 2020 held by HealthTech For Care, an endowment fund launched by France Biotech, and co-organised with EIT Health, will accelerate patient access to healthcare solutions and contribute to building a stronger ecosystem.

Maryvonne Hiance

President of HTID®

Europe is a land of innovation in health with many start-up and SME’s looking for financing to make their innovations available to patients and to meet the medical challenges of tomorrow. The objective of the HTID® is to become a reference place for exchanges between European HealthTech companies, international investors and pharmaceutical groups.

Jean-Marc Bourez

Managing Director of EIT Health France and Head of the VCoE

We are thrilled to partner with HTFC to support the extensive developments taking place in European HealthTech, and to help accelerate this work to improve patient quality of life by promoting HTID. This ideal event brings together new VCoE members and the broader LifeScience investment community for the first time as VCoE’s operational teams will be based in Paris.

Franck Mouthon

President of France Biotech and CEO of Theranexus

Thanks to the innovations it develops for the benefit of patients, the HealthTech industry constitutes indeed a major societal issue for health. We created this event with patients’ best interests in mind to ultimately reach patients. These developments are characterized by large funding needs and long durations.

What will you attend to?

Private meetings

To set up partnerships between European innovative companies and their growth supporters

Conferences & thematic panels

On specific topics supervised by well-known international scientific Key Opinion Leaders

Networking events

To gather the ecosystem

Be part of the European investment hub supporting European HealthTech companies development. Accelerate innovation by setting a privilege place between C-level executives from the most European innovative companies in HealthTech, worldwide investors, pharmaceutical companies, KOLs, experts and institutional representatives.

France is home to the largest number of life sciences start-ups in Europe. This fast-moving industry is facing disruptive innovations, which generate myriad complex legal issues, and we are glad as an international law firm to work alongside France Biotech to support businesses in the sector.

Alain Decombe Managing partner of Dechert's Paris office

It was great to attend and support HTID’s first edition. As the only American pharma company partner, this event was the opportunity for us to formalize our desire to invest in innovation in France and increase our synergies with many start-ups. (...) France is definitely a center of excellence in e-health, artificial intelligence and big data but also in biotech start-ups. We hope to be there next year with possible new partners and wish to be even more involved in the French innovation ecosystem.

Corinne Blachier-Poisson Chairman of Amgen France

We are delighted to have participated to this 1st edition of the HTID. As a Belgian company, we can only applaud the support given by the French government to the European health ecosystem. In addition to bringing together the best companies in the sector and specialized investors, this event brings high visibility on a sector creating direct and indirect qualified jobs. Gathering all actors in this value chain can only be virtuous, allowing academic research to find an industrial outlet.

Filippo Petti CEO of Celyad

Targeted European Innovative Companies' Criteria

Open to private and listed companies

Biotech

At least on-going Phase 1, financement available for Phase 2

Medtech

CE or FDA filed (PMA, DeNovo, 510k, pre-subs) product

Innovative Med activities

Innovative services and functionalities under test by HealthTech partners

Digital Health

Services or functionalities in development with at least 1 fund raising

Want to work together?

Check out our partnership offers and join us on this must-attend HealthTech innovation event.
Become a part of the movement to foster stronger collaborations and partnerships within Europe to improve patient lives in the EU and beyond!

Partnership offers